Women experience higher rates of adverse events during hepatitis C virus therapy in HIV infection: A meta-analysis

Journal of Acquired Immune Deficiency Syndromes

Volumn 55, Issue 2, 2010, Pages 170-175

  Bhattacharya, Debika ^a   Umbleja, T ^b   Carrat, F ^c   Chung, R T ^d   Peters, M G ^e   Torriani, F ^f   Andersen, J ^b   Currier, J S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HÔPITAL SAINT ANTOINE   (France)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Drug therapy; Hepatitis C virus; HIV; Sex differences; Toxicity

Indexed keywords

ALPHA2A INTERFERON; HEMOGLOBIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA; ZIDOVUDINE; ALPHA INTERFERON; ANTIVIRUS AGENT; INTERFERON; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ANEMIA; ARTICLE; BODY MASS; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; DEPRESSION; DRUG DOSE ESCALATION; DRUG WITHDRAWAL; FEMALE; GENDER; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MIXED INFECTION; NEUTROPENIA; NEUTROPHIL COUNT; PREDICTOR VARIABLE; PRIORITY JOURNAL; SENESCENCE; SEX RATIO; SYSTEMATIC REVIEW; COMPLICATION; HIV INFECTIONS; KAPLAN MEIER METHOD; MIDDLE AGED; RISK; SEX DIFFERENCE;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; INTERFERONS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; ODDS RATIO; POLYETHYLENE GLYCOLS; RIBAVIRIN; SEX FACTORS; INTERFERON-ALPHA; KAPLAN-MEIER ESTIMATE; RECOMBINANT PROTEINS;

EID: 77957307922     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181e36420     Document Type: Article

References (27)

1. Sherman KE, Rouster SD, Chung RT, et al. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: A crosssectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34:831-837.
2. Staples CT Jr, Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis. 1999;29:150-154.
3. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492-497.
4. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: A randomized controlled trial. JAMA. 2004;292: 2839-2848.
5. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451-459.
6. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa- 2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438-450.
7. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
8. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet. 2001;358:958-965.
9. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl JMed. 1998;339:1485-1492.
10. Sulkowski MS, Wasserman R, Brooks L, et al. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat. 2004;11:243-250.
11. Gohier B, Goeb JL, Rannou-Dubas K, et al. Hepatitis C, alpha interferon, anxiety and depression disorders: A prospective study of 71 patients. World J Biol Psychiatry. 2003;4:115-118.
12. Koskinas J, Merkouraki P, Manesis E, et al. Assessment of depression in patients with chronic hepatitis: effect of interferon treatment. Dig Dis. 2002;20:284-288.
13. Fontana RJ, Schwartz SM, Gebremariam A, et al. Emotional distress during interferon-alpha-2B and ribavirin treatment of chronic hepatitis C. Psychosomatics. 2002;43:378-385.
14. Currier JS, Spino C, Grimes J, et al. Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team. J Acquir Immune Defic Syndr. 2000;24:316-324.
15. Moore RD, Fortgang I, Keruly J, et al. Adverse events from drug therapy for human immunodeficiency virus disease. Am J Med. 1996;101:34-40. (Pubitemid 26285938)
16. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Statist Assoc. 1999;94:496-509.
17. Touloumi G, Pantazis N, Antoniou A, et al. Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences. J Acquir Immune Defic Syndr. 2006;42:554-561.
18. d'Arminio Monforte A, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS. 2000;14:499-507.
19. Mocroft A, Youle M, Moore A, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS. 2001;15:185-194.
20. Tedaldi EM, Absalon J, Thomas AJ, et al. Ethnicity, race, and gender. Differences in serious adverse events among participants in an antiretroviral initiation trial: results of CPCRA 058 (FIRST Study). J Acquir Immune Defic Syndr. 2008;47:441-448.
21. Bersoff-Matcha SJ, Miller WC, Aberg JA, et al. Sex differences in nevirapine rash. Clin Infect Dis. 2001;32:124-129.
22. Boxwell DESB. Lactic acidosis (LA) in patients receiving nucleoside reverse transcriptase inhibitors (NRTIs) [abstract 1284]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 26-29, 1999, San Francisco, CA.
23. Smith CJ, Sabin CA, Youle MS, et al. Response to efavirenz-containing regimens in previously antiretroviral-naive HIV-positive patients: the role of gender. J Acquir Immune Defic Syndr. 2007;46:62-67.
24. Burger D, van der Heiden I, la Porte C, et al. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol. 2006;61:148-154.
25. Raison CL, Demetrashvili M, Capuron L, et al. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs. 2005;19:105-123.
26. Snoeck E, Wade JR, Duff F, et al. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa- 2a (40KD) plus ribavirin. Br J Clin Pharmacol. 2006;62:699-709.
27. Anderson PL, Kakuda TN, Kawle S, et al. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS. 2003;17:2159-2168.